Czech Republic

Pharmacovigilance activities in the Czech Republic are regulated by the State Institute for Drug Control (SÚKL) under EU pharmacovigilance legislation and EU GVP. The MAH must operate an EU-compliant pharmacovigilance system, appoint an EU/EEA QPPV, maintain a PSMF in the EU/EEA and meet EU requirements for EudraVigilance reporting, PSURs and RMPs. Under the current SÚKL PHV-6 requirements, all MAHs must appoint and notify a contact person for pharmacovigilance questions in the Czech Republic; national Czech-language case/literature requirements also apply. The system remains subject to pharmacovigilance inspection. As an EU/EEA jurisdiction, the EU pharmacovigilance framework applies to the EU QPPV and Union PSMF, EudraVigilance ICSR reporting, applicable PSURs, RMPs, signal management, quality-system audits and competent-authority inspections. MAHs should also check current national submission channels, contact arrangements and language requirements. BAUPHARMA supporting resources (operational context only, not national regulatory evidence): Difference in QPPV Nomination Between EU and KSA; PSMF Maintenance: Concept and Importance in Pharmacovigilance.